A recombinant FVIII to prevent and control bleeding in people with hemophilia A1
Novoeight®—designed
to fit into their world
RELIA BIL IT Y
0
INHIBITORS CONFIRMED1
One of the largest clinical trials with no inhibitors
confirmed in 213 previously treated patientsa,b
PU RITY
20
-NM FILTERS4
Employs state-of-the-art double nanofiltration
POR TA B IL IT Y
UP TO
David, 22 years old,
lives with hemophilia A
Visit NovoeightPro.com
today to learn more.
86 F
o
FOR 12 MONTHS1
Highest storage temperature for the longest durationc
Please see Prescribing Information for complete storage instructions.
a
Patients with previous inhibitors were excluded from the trial. Individuals with hemophilia A may develop inhibitors to FVIII. Monitor patients taking Novoeight ® for inhibitor formation.1
guardian™1: a multicenter, multinational, open-label, single-arm efficacy and safety trial in 150 patients (aged 12 to 65 years) with severe hemophilia A on a prophylactic treatment regimen
who we